Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult3. fázis

Open-label Study of Plozasiran in Adolescents (age 12 to <18 years) with Familial Chylomicronemia Syndrome

A legfontosabb adatok

Ki végzi
Arrowhead Pharmaceuticals Inc.
Hol
Ausztria, Hollandia és Olaszország4 helyszín, 3 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
3. fázis
Résztvevők
4 fő, tervezett
Kezdés
2027. márc. 15.
Várható befejezés
2030. szept. 30.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. november 11.

Ki vehet részt

Életkor
Legfeljebb 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Adolescent males or nonpregnant (who do not plan to become pregnant), nonlactating females 12 to <18 years of age
  • Participant and parent (or legally authorized representative) able and willing to provide written informed consent/assent and any authorization required by law prior to the performance of any study-specific procedures
  • Fasting TG ≥880 mg/dL (approximately ≥10 mmol/L) at screening, that is refractory to standard lipid-lowering therapy (sample drawn after at least 3 months on stable lipid lowering regimen, including statins, omega-3 fatty acids, and/or fibrates). Two additional repeat tests are allowed to qualify
  • Confirmed homozygote, compound heterozygote, or double heterozygote for known loss-of-function mutations in FCS-causing genes (such as LPL, and LPL related APOC2, APOA5, lipase maturation factor 1 [LMF1], or glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 [GPIHBP1]), based on genotype sample collected at screening visit and analyzed at the study reference laboratory. If a participant is identified as having, or is suspected of having, a congenital or inherited disorder of lipid metabolism other than FCS that could independently cause or contribute to severe hypertriglyceridemia, including an inherited lipodystrophy syndrome, the participant’s eligibility must be evaluated by the Investigator in consultation with the Sponsor Medical Monitor. The participant may proceed to randomization only if prior written approval is obtained from the Sponsor Medical Monitor. The assessment, eligibility determination, and rationale must be documented in the study records
  • Willing to follow dietary counseling as per PI judgment based on local standard of care, consistent with an intake of ≤20 g of fat per day during the study
  • If on medications for management of Type 2 diabetes, or other restricted medications specified in the protocol, the dosing regimen must be stable for 3 months before collection of qualifying lipid parameter at screening
  • Female participants of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 90 days after the EOS or the last dose of IMP, whichever is later. Male participants must agree to use a condom during the study and for at least 90 days after the EOS or the last dose of IMP, whichever is later. Participants must not donate sperm or eggs during the study and for at least 90 days after the EOS or last dose of IMP, whichever is later. Female participants of childbearing potential on hormonal contraceptives must be stable on the medication for >1 menstrual cycle prior to Day 1

Ki nem vehet részt

  • Use of any hepatocyte-targeted siRNA that targets lipids and/or triglycerides within 365 days before Day 1
  • On treatment with anti-retroviral therapy for HIV infection or known history of HIV infection
  • Active infection requiring antibacterial or antiviral therapy that will not be completed prior to study Day 1
  • Use of an investigational agent or device within 30 days or within 5 half-lives, based on plasma PK (whichever is longer) prior to Day 1 or current participation in an interventional investigational study. Participants previously exposed to plozasiran or ARO-ANG3 will require a washout period of at least 1 year from last dose
  • Any concomitant medical or psychiatric condition or social situation or any other situation that, in the PI’s judgment, would make it difficult to comply with protocol requirements or put the participant at additional safety risk
  • Active pancreatitis within 12 weeks before Day 1
  • Use of any of the following: a. Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or planned use during the study. b. Plasma apheresis within 4 weeks prior to Day 1 or planned during the study. c. Blood donation of 50 to 499 mL within 4 weeks of qualifying lipid parameter collection or of >499 mL within 8 weeks of qualifying lipid parameter collection
  • Known history of or seropositive (hepatitis B surface antigen [HbsAg] +) for hepatitis B virus (HBV) or hepatitis C virus (HCV) (HCV seropositivity requires positive test for antibodies confirmed with positive test for HCV RNA)
  • History of bleeding diathesis or coagulopathy
  • Current diagnosis of nephrotic syndrome or chronic kidney disease
  • History of malignancy
  • History of alcoholism or drug abuse within one year of Day 1
  • Known hypersensitivity to the active substance or to any of the excipients of plozasiran
  • History of major surgery within 12 weeks of Day 1
  • Uncontrolled thyroid disease with clinical evidence of primary hypothyroidism (screening thyroid-stimulating hormone [TSH] >ULN and free thyroxine [T4] ULN and free T4 within normal limit [WNL]), or secondary hypothyroidism (screening TSH
  • Diabetes mellitus with any of the following: a. Newly diagnosed within 12 weeks of screening. b. HbA1c ≥9.0% at screening
  • Any of the following laboratory values at screening: a. ALT or AST ≥3×ULN at screening. b. Total bilirubin ≥1.5×ULN (if the participant has a prior diagnosis and documentation of Gilbert’s syndrome, then total bilirubin must be ≤3 mg/dL at screening). c. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 at screening, using the Bedside Schwartz Formula. d. Persistent proteinuria: spot urine protein/spot urine creatinine ratio greater than 200 mg/day (confirmed on 2 tests 7 days apart). e. Clinically significant abnormality in prothrombin time, partial thromboplastin time (PTT), or INR. f. LDL cholesterol >130 mg/dL at screening. g. Persistent positive hematuria: >5 red blood cells per high power field (confirmed on 2 tests 7 days apart)
  • Uncontrolled hypertension (>95th percentile based on age, gender, and height percentile); if untreated, participant may be rescreened once hypertension is treated and controlled
  • Use of any other hepatocyte-targeted siRNA or ASO molecule within 60 days or within 5 half-lives before Day 1 based on plasma PK, whichever is longer
  • Body weight <35 kg

Hol van ez a vizsgálat?

3 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To evaluate the activity, PK, and PD of plozasiran in pediatric (adolescent) participants (age 12 to <18 years) with FCS.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Open-Label Study to Evaluate the Activity, Pharmacokinetics, Pharmacodynamics, And Safety of Plozasiran in Adolescents (Age 12 to <18 Years) With Familial Chylomicronemia Syndrome
A regiszteradat frissítve
2026. november 11.